Compound reference
This combination brings together BPC-157, Cartalax. Explore each component’s research focus below, followed by the evidence for the combination.
BPC-157 is studied for processes involved in tendon and connective-tissue repair, including collagen organization and cellular responses to injury. The potential application is tissue recovery, supported here by preclinical findings rather than established clinical benefits.
Cartalax-related research explores cell renewal and stress responses. The cited work concerns tissue cultures; it does not establish the joint or cartilage benefits sometimes associated with its catalog name.
Explore the selected studies, their findings and their limits.
A rat Achilles-tendon injury experiment reported improved tendon strength, functional measures and collagen organization with BPC-157 compared with controls. A separate study in rat tendon fibroblasts found increased growth-hormone receptor expression. Together, these findings explain interest in tissue-repair signaling, but neither study demonstrates healing, pain relief or safety in people or dogs.
Research on the AED peptide, also called T-31, in rat kidney tissue cultures reported changes in proliferation and apoptosis markers. This is evidence about cultured kidney cells, not a demonstration of cartilage repair or relief of canine arthritis. The cited study does not establish clinical joint outcomes in dogs.
The sources above examine individual constituents or related molecules. They do not test this exact combination. A combined effect, improved recovery or greater safety cannot be inferred by adding the individual findings together.
The studies discussed here do not establish the safety or effectiveness of this catalog formula in dogs. Rat, mouse, cell-culture and human findings are not canine clinical results; they also do not establish absorption or effects from the listed oral formula.
For more information, contact info@aurevixpeptides.com.
Editorial review: September 23, 2026
